Ultimovacs Balance Sheet Health
Financial Health criteria checks 6/6
Ultimovacs has a total shareholder equity of NOK191.0M and total debt of NOK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NOK215.8M and NOK24.8M respectively.
Key information
0%
Debt to equity ratio
NOK 0
Debt
| Interest coverage ratio | n/a |
| Cash | NOK 131.00m |
| Equity | NOK 191.01m |
| Total liabilities | NOK 24.78m |
| Total assets | NOK 215.79m |
Recent financial health updates
Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth
Feb 21
Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business
Oct 26Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth
Oct 05Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans
May 19Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation
Jul 27Recent updates
Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth
Feb 21Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business
Oct 26Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth
Oct 05Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans
May 19Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation
Jul 27Financial Position Analysis
Short Term Liabilities: ULTI's short term assets (NOK140.1M) exceed its short term liabilities (NOK12.3M).
Long Term Liabilities: ULTI's short term assets (NOK140.1M) exceed its long term liabilities (NOK12.5M).
Debt to Equity History and Analysis
Debt Level: ULTI is debt free.
Reducing Debt: ULTI had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ULTI has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ULTI has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 22% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 04:32 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ultimovacs ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Geir Holom | DNB Markets |
| Christian Binder | Redeye |